ALL |
META-ANALYSIS |
CITATIONS |
|
Benefit-Cost Summary Statistics Per Participant | ||||||
---|---|---|---|---|---|---|
Benefits to: | ||||||
Taxpayers | $2,351 | Benefits minus costs | $11,425 | |||
Participants | $2,714 | Benefit to cost ratio | $52.64 | |||
Others | $1,325 | Chance the program will produce | ||||
Indirect | $5,256 | benefits greater than the costs | 63 % | |||
Total benefits | $11,646 | |||||
Net program cost | ($221) | |||||
Benefits minus cost | $11,425 | |||||
Meta-Analysis of Program Effects | ||||||||||||
Outcomes measured | Treatment age | No. of effect sizes | Treatment N | Adjusted effect sizes(ES) and standard errors(SE) used in the benefit - cost analysis | Unadjusted effect size (random effects model) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
First time ES is estimated | Second time ES is estimated | |||||||||||
ES | SE | Age | ES | SE | Age | ES | p-value | |||||
Illicit drug use disorder Clinical diagnosis of illicit drug use disorder or symptoms measured on a validated scale. When possible, we exclude cannabis/marijuana use disorder from this outcome. |
30 | 2 | 172 | -0.703 | 0.193 | 30 | 0.000 | 0.187 | 33 | -0.703 | 0.001 |
Detailed Monetary Benefit Estimates Per Participant | ||||||
Affected outcome: | Resulting benefits:1 | Benefits accrue to: | ||||
---|---|---|---|---|---|---|
Taxpayers | Participants | Others2 | Indirect3 | Total |
||
Illicit drug use disorder | Criminal justice system | $5 | $0 | $14 | $3 | $22 |
Labor market earnings associated with illicit drug abuse or dependence | $829 | $1,947 | $0 | $0 | $2,776 | |
Health care associated with illicit drug abuse or dependence | $1,275 | $197 | $1,310 | $638 | $3,420 | |
Mortality associated with illicit drugs | $242 | $569 | $0 | $4,727 | $5,538 | |
Program cost | Adjustment for deadweight cost of program | $0 | $0 | $0 | ($111) | ($111) |
Totals | $2,351 | $2,714 | $1,325 | $5,256 | $11,646 | |
Detailed Annual Cost Estimates Per Participant | ||||
Annual cost | Year dollars | Summary | ||
---|---|---|---|---|
Program costs | $204 | 2013 | Present value of net program costs (in 2018 dollars) | ($221) |
Comparison costs | $0 | 2013 | Cost range (+ or -) | 10 % |
Benefits Minus Costs |
Benefits by Perspective |
Taxpayer Benefits by Source of Value |
Benefits Minus Costs Over Time (Cumulative Discounted Dollars) |
The graph above illustrates the estimated cumulative net benefits per-participant for the first fifty years beyond the initial investment in the program. We present these cash flows in discounted dollars. If the dollars are negative (bars below $0 line), the cumulative benefits do not outweigh the cost of the program up to that point in time. The program breaks even when the dollars reach $0. At this point, the total benefits to participants, taxpayers, and others, are equal to the cost of the program. If the dollars are above $0, the benefits of the program exceed the initial investment. |
Baker, A., Boggs, T.G., Lewin, T.J. (2001) Randomized controlled trial of brief cognitive-behavioural interventions among regular users of amphetamine. Addiction 96(9), 1279-1287.
Baker, A., Lee, N.K., Claire, M., Lewin, T.J., Grant, T., Pohlman, S., et al (2005). Brief Cognitive Behavioural Interventions for Regular Amphetamine Users: A Step in the Right Direction. Addiction, 100,(3), 367-378.